Retrospective study investigated the effect sequence has on overall survival in patients with melanoma brain metastases treated with a combination of SRS, WBRT, immunotherapy, or targeted therapy.
A review of medical records revealed that thyroid function may be affected by immune checkpoint inhibitor therapy, and these patients should undergo thyroid function tests, especially during the first 8 weeks of therapy.
In this study, researchers sought to determine if use of a tumor specific vaccine would improve the efficacy of PD-1 immune checkpoint inhibition in patients with incurable HPV-16 cancer.
In this retrospective study, researchers sought to determine if cancer patients with rheumatologic disease would be able to tolerate cancer treatment with immune checkpoint inhibitors or if these agents would induce a rheumatologic disease flare.
Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.
A small number of patients with cancer treated with immune checkpoint inhibitors may have higher-than-usual risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a case report on 13 patients has shown.
